The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...

One ALS patient received TRE-515 under the FDA program last year, and early signs suggest the therapy may help stabilize ...

ALS patients and caregivers prefer care models where multiple specialists are seen during the same visit. They prioritize team-based care and ALS expertise over factors like visit length or cost.

The new project combines clinical data with advanced analytics and artificial intelligence in an effort to create ...

ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.

Eric Dane not only battled ALS, but also advocated for others fighting the disease before his death. Dane’s work as an ALS ...

Every few months for the past three years, Jeff Vierstra has been receiving infusions in his spine that target and disable a ...

Cheryl Fleming never expected to become ill with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

Columbia's Silence ALS program is testing spinal antisense therapy in a high‑risk patient; early EMG tests normalized.

Amyotrophic lateral sclerosis, or ALS, is a progressive disease that attacks the brain and spinal cord, robbing people of ...